FDA Grants Orphan Drug Designation To Juno's JCAR015 Leukemia T Cell Product Candidate

Share this content:
FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate
FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate
Juno Therapeutics, Inc. announced today that the FDA has granted Orphan Drug Designation to its JCAR015 chimeric antigen receptor product candidate. The designation was granted for treatment of acute lymphoblastic leukemia. JCAR015 Phase I trials are currently underway at Juno's collaboration partner, Memorial Sloane Kettering Cancer Center.
READ FULL ARTICLE From News Medical
Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


is free, fast, and customized just for you!

Already a member?

Sign In Now »